Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constanze Schmidt

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
JACC. Heart Failure|December 3, 2025
Criteria Adrift: Reframing Iron Deficiency in Heart FailureStephan von Haehling, Constanze Schmidt, Stefan D Anker
International Journal of Molecular Sciences|September 9, 2022
Distress-Mediated Remodeling of Cardiac Connexin-43 in a Novel Cell Model for Arrhythmogenic Heart DiseasesCarl-Mattheis Wahl, Constanze Schmidt, Markus Hecker, et al.
Frontiers in Pharmacology|February 11, 2020
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium ChannelsAntonius Ratte, Felix Wiedmann, Manuel Kraft, et al.
Journal of Experimental Botany|October 23, 2024
Hybrid grain production in wheat benefits from synchronized flowering and high female flower receptivityConstanze Schmidt, Valentin Hinterberger, Norman Philipp, et al.
Vascular Health and Risk Management|April 15, 2011
The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillationConstanze Schmidt, Jana Kisselbach, Patrick A Schweizer, et al.
European Journal of Pharmacology|June 15, 2014
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic conceptConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Progress in Biophysics and Molecular Biology|June 20, 2020
Mechanosensitive TREK-1 two-pore-domain potassium (K<sub>2P</sub>) channels in the cardiovascular systemFelix Wiedmann, Susanne Rinné, Birgit Donner, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K<sub>2P</sub>3.1 (TASK-1) ChannelsConstanze Schmidt, Felix Wiedmann, Anne-Rike Gaubatz, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 14, 2012
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
European Journal of Pharmacology|September 28, 2013
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
JACC. Heart Failure|December 3, 2025
Criteria Adrift: Reframing Iron Deficiency in Heart FailureStephan von Haehling, Constanze Schmidt, Stefan D Anker
International Journal of Molecular Sciences|September 9, 2022
Distress-Mediated Remodeling of Cardiac Connexin-43 in a Novel Cell Model for Arrhythmogenic Heart DiseasesCarl-Mattheis Wahl, Constanze Schmidt, Markus Hecker, et al.
Frontiers in Pharmacology|February 11, 2020
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium ChannelsAntonius Ratte, Felix Wiedmann, Manuel Kraft, et al.
Journal of Experimental Botany|October 23, 2024
Hybrid grain production in wheat benefits from synchronized flowering and high female flower receptivityConstanze Schmidt, Valentin Hinterberger, Norman Philipp, et al.
Vascular Health and Risk Management|April 15, 2011
The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillationConstanze Schmidt, Jana Kisselbach, Patrick A Schweizer, et al.
European Journal of Pharmacology|June 15, 2014
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic conceptConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Progress in Biophysics and Molecular Biology|June 20, 2020
Mechanosensitive TREK-1 two-pore-domain potassium (K<sub>2P</sub>) channels in the cardiovascular systemFelix Wiedmann, Susanne Rinné, Birgit Donner, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K<sub>2P</sub>3.1 (TASK-1) ChannelsConstanze Schmidt, Felix Wiedmann, Anne-Rike Gaubatz, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 14, 2012
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
European Journal of Pharmacology|September 28, 2013
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channelsConstanze Schmidt, Felix Wiedmann, Patrick A Schweizer, et al.
Pageof 10